In 2006, the induced pluripotent stem cell (iPSC) was presented to the world, paving the way for the development of a magnitude of novel therapeutic alternatives, addressing a diverse range of diseases. However, despite the immense cell therapy potential, relatively few clinical trials evaluating iPSC-technology have actually translated into interventional, clinically applied treatment regimens. Herein, our aim was to determine trends in globally conducted clinical trials involving iPSCs. Data were derived both from well-known registries recording clinical trials from across the globe, and databases from individual countries. Comparisons were firstly drawn between observational and interventional studies before the latter was further analyzed in terms of therapeutic and nontherapeutic trials. Our main observations included global distribution, purpose, target size, and types of disorder relevant to evaluated trials. In terms of nontherapeutic trials, the USA conducted the majority, a large average number of participants—187—was included in the trials, and studies on circulatory system disorders comprised a slightly higher proportion of total studies. Conversely, Japan was the frontrunner in terms of conducting therapeutic trials, and the average number of participants was much lower, at roughly 29. Disorders of the circulatory, as well as nervous and visual systems, were all studied in equal measure. This review highlights the impact that iPSC-based cell therapies can have, should development thereof gain more traction. We lastly considered a few companies that are actively utilizing iPSCs in the development of therapies for various diseases, for whom the global trends in clinical trials could become increasingly important.

Graphical Abstract

中文翻译：

---

回顾目前涉及诱导多能干细胞的临床试验趋势

2006 年，诱导多能干细胞 (iPSC) 向世界展示，为开发大量新的治疗替代品铺平了道路，以应对各种疾病。然而，尽管有巨大的细胞治疗潜力，但评估 iPSC 技术的临床试验相对较少，实际上已经转化为介入性、临床应用的治疗方案。在此，我们的目标是确定全球开展的涉及 iPSC 的临床试验的趋势。数据来自记录全球临床试验的知名登记处和各个国家的数据库。首先在观察性研究和干预性研究之间进行比较，然后再根据治疗性和非治疗性试验对后者进行进一步分析。我们的主要观察包括全球分布，目的、目标大小和与评估试验相关的疾病类型。在非治疗性试验方面，美国进行了大部分试验，试验中平均有大量参与者（187 人），循环系统疾病研究占总研究的比例略高。相反，日本在进行治疗试验方面处于领先地位，参与者的平均人数要少得多，约为 29 人。循环系统疾病以及神经和视觉系统的研究都以同等程度进行。这篇综述强调了基于 iPSC 的细胞疗法可以产生的影响，如果其发展获得更多牵引力的话。我们最后考虑了一些积极利用 iPSC 开发各种疾病疗法的公司，

图形概要